Sugi Predict

Sugi Predict / Compounds / SCHEMBL3440264

SCHEMBL3440264

SCHEMBL3440264

O=C(O)CCC(=O)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.53
▸ EGLN1 Q9GZT9 2/20 0.53
▸ ALKBH5 Q6P6C2 1/20 0.53
▸ SUCNR1 Q9BXA5 1/20 0.53
▸ FAAH O00519 11/20 0.48
▸ CES1 P23141 8/20 0.46
▸ CES2 O00748 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ SLC15A2 Q16348 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SLC13A3 Q8WWT9 1/20 0.41
▸ OR51E2 Q9H255 1/20 0.41
▸ SLC22A6 Q4U2R8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11533523 0.87 FAAH (0.57) FAAHCES1CES2MEN1CYP1A2
SCHEMBL23896902 0.83 SLC22A6 (0.58) LMNAFAAHCES1CES2MEN1
Succinic Acid SCHEMBL29896408 0.81 LMNA (0.60) LMNAEGLN1ALKBH5SUCNR1MEN1
Succinic Acid SCHEMBL29896406 0.81 LMNA (0.60) LMNAEGLN1ALKBH5SUCNR1MEN1
SCHEMBL10697629 0.81 FAAH (0.64) LMNAFAAHCES1CES2MEN1
SCHEMBL7371814 0.81 FAAH (0.64) LMNAFAAHCES1CES2MEN1
SCHEMBL2222667 0.81 FAAH (0.64) LMNAFAAHCES1CES2MEN1
SCHEMBL9839928 0.79 EGLN1 (0.50) LMNAEGLN1ALKBH5SUCNR1FAAH
Ethylene Glycol SCHEMBL17765474 0.79 FAAH (0.50) FAAHCES1CES2MEN1CYP1A2
SCHEMBL1712961 0.74 FAAH (0.46) FAAHCES1CES2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3882252-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2025-11-19 — — EP disclosed
EP-3882252-A1 BETA-LACTAMASE INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2021-09-22 — — EP disclosed
US-11008346-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2021-05-18 — — US disclosed
EP-3154989-B1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2021-03-24 — — EP disclosed
US-20200361962-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-11-19 — — US disclosed
US-9926336-B2 Beta-lactamase inhibitors VENATORX PHARMACEUTICALS (US) 2018-03-27 — — US disclosed
US-20170342092-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-30 — — US disclosed
US-9783555-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2017-10-10 — — US disclosed
US-20170226135-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-10 — — US disclosed
US-9637504-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2017-05-02 — — US disclosed
US-7807841-B2 Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors IRM LLC (BM) 2010-10-05 — — US disclosed
US-20090124597-A1 SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-05-14 — — US disclosed
EP-1850844-A2 SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM, LLC (BM) 2007-11-07 — — EP disclosed
WO-2006104594-A2 SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-10-05 — — WO disclosed
CN-1045590-C Hydrazine derivative and application of same NIHON NOHYAKU CO LTD (JP) 1999-10-13 — — CN disclosed
CN-1107142-A Hydrazine derivative and application of same NIHON NOHYAKU CO LTD (JP) 1995-08-23 — — CN disclosed
EP-0413807-A1 ACYLATED POLYAMINES AND APPLICATIONS THEREOF AS VEGETABLE GROWTH REGULATORS ROUSSEL-UCLAF (FR) 1991-02-27 — — EP disclosed
WO-1990010386-A1 ACYLATED POLYAMINES AND APPLICATIONS THEREOF AS VEGETABLE GROWTH REGULATORS ROUSSEL-UCLAF (FR) 1990-09-20 — — WO disclosed
EP-0376819-A1 Acrylated polyamines, process for their preparation and their use as fungicides ROUSSEL-UCLAF (FR) 1990-07-04 — — EP disclosed
US-4326071-A ENZYME INHIBITORS AND ANTIBIOTICS MERRELL TORAUDE ET COMPAGNIE (FR) 1982-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008346-B2 Beta-lactamase inhibitors MGAM, GAA, LCT LMNA 542/4885EGLN1 797/4885ALKBH5 680/4885
US-20170342092-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT LMNA 542/4885EGLN1 797/4885ALKBH5 680/4885
US-20200361962-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT LMNA 542/4885EGLN1 797/4885ALKBH5 680/4885
US-20170226135-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT LMNA 542/4885EGLN1 797/4885ALKBH5 680/4885
US-20090124597-A1 SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR3C2, NR5A1, ESRRA LMNA 609/4885EGLN1 2695/4885ALKBH5 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.